Needle-free vaccine innovator banks $34m

Source: Australian Financial Review

06 December 2022

We couldn’t be happier to have been a part of the latest financing round for Vaxxas – a company that OneVentures has been supporting for a very long time, with good reason.

The development of the nanopatch to deliver needle-free vaccines has massive global potential. We are now witnessing the pivotal stages in the company’s development: an in-human clinical trial that is now actively recruiting and the commercialisation of production through building a new manufacturing centre in Brisbane.

It is extremely gratifying to see companies grow from early stages to being on the cusp of changing how vaccines are delivered around the world. Read the full article in the Australian Financial Review

Posted in — AFR

You may also like

27 February 2013

Who’s disrupting your industry? Meet 10 start-ups eager to eat the big boys’ lunch

06 August 2018

OneVentures readies Australian VC first: $100m credit fund

14 November 2017

Grant Chamberlain joins OneVentures

01 February 2022

Vale Grant Chamberlain

AFR, Announcement

04 July 2021

Hivery scores debt from OneVentures in 10th credit deal

16 March 2020

Why 20-year-old Aussie tech firm is taking on start-up style funding

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor